Canada markets close in 4 hours 1 minute

Evofem Biosciences, Inc. (EVFM)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.0110-0.0020 (-15.38%)
As of 11:43AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0130
Bid0.0110 x 0
Ask0.0111 x 0
Day's Range0.0110 - 0.0130
52 Week Range0.0100 - 1.4000
Avg. Volume1,005,282
Market Cap682,664
Beta (5Y Monthly)-0.65
PE Ratio (TTM)0.01
EPS (TTM)1.7400
Earnings DateAug 12, 2024 - Aug 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

    Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.

  • PR Newswire

    Evofem Biosciences Announces Financial Results for the First Quarter of 2024

    The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include:

  • PR Newswire

    Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO

    Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 17/823,020 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.